Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
| Autor: | L. Eugene Arnold, Michael G. Aman, Amelia M. Cook, Susan Thompson, Yaser Ramadan, Andrea N. Witwer, Kristy L. Hall |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Adolescent Population Pilot Projects Atomoxetine Hydrochloride Placebo Double-Blind Method mental disorders Developmental and Educational Psychology medicine Humans Attention deficit hyperactivity disorder Autistic Disorder Child Psychiatry education Pervasive developmental disorder not otherwise specified education.field_of_study Cross-Over Studies Adrenergic Uptake Inhibitors Propylamines Atomoxetine medicine.disease Developmental disorder Psychiatry and Mental health Attention Deficit Disorder with Hyperactivity Autism Female Psychology medicine.drug Atomoxetine hydrochloride |
| Zdroj: | Journal of the American Academy of Child & Adolescent Psychiatry. 45:1196-1205 |
| ISSN: | 0890-8567 |
| DOI: | 10.1097/01.chi.0000231976.28719.2a |
| Popis: | Objective To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6 weeks each, separated by 1-week washout. Slopes for each condition were compared by paired t test. Results In 2004-2005, 12 boys and 4 girls (7 with autistic disorder, 1 Asperger's, 8 pervasive developmental disorder not otherwise specified) all completed at least 3 weeks of each condition. On the primary outcome, the Hyperactivity subscale of the Aberrant Behavior Checklist, ATX was superior to placebo ( p =.043, effect size d = 0.90). It was also superior on a 0 to 3 rating of nine DSM-IV ADHD hyperactive/impulsive symptoms ( p =.005, d = 1.27), but missed significance on nine inattentive symptoms ( p =.053, d = 0.89). Nine subjects responded to ATX, four to placebo (25% improvement on the Hyperactivity subscale plus Clinical Global Impressions-Improvement of 1-2. One was rehospitalized for recurrent violence on ATX. Adverse events were otherwise tolerable, with no tendency to stereotypy. Conclusions ATX appears safe and effective for treating hyperactivity in some children with autism spectrum disorders. The effect appears as large as in a multisite methylphenidate trial in the same population, with fewer intolerable side effects. Further study in autism spectrum disorders is indicated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|